AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05487053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-shot adductor canal block
Description: Postoperative analgesia in this group will be carried out by a single-shot bolus of 20 ml Ropivacaine 0.5% in the region of the middle third of the adductor canal.
Study NCT05487053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral nerve block
Description: Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed to the femoral nerve in the area of the femoral triangle. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
Study NCT04792372 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initial periodontal treatment
Description: Conventional periodontal treatment (scaling and root debridement) will be conducted
Study NCT05282589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbopelvic manipulation and conventional therapy
Description: Lumbopelvic manipulation was given along with conventional physical therapy~Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes.
Study NCT05282589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes.
Study NCT05029609 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal Foralumab Solution
Description: The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.
Study NCT05029609 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
Study NCT06000553 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling at inclusion, 6 months, 1 year and 2 years. Tumor and intracystic fluid samples are taken only if a biopsy is planned following MRI results.
Description: If the patient agrees to take part in the study, he or she will have a blood sample taken from 8 x 4 ml EDTA tubes at the time of inclusion in the trial.Then, at 6 months (+/- 1 month), 1 year and 2 years, the patient will have the same blood sample as at inclusion.If a biopsy is performed as part of routine care, a tumor sample will be taken and sent to the IPC pathology department for FFPE block. If a biopsy is performed and the patient consents, a cystic fluid sample will be taken.
Study NCT05180981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: Noninvasive stimulation vs sham stimulation will be delivered via an auricular device.
Study NCT05180981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing task
Description: Participants will be asked to breathe in specific patterns.
Study NCT04785768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride Injection
Description: Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.
Study NCT04785768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride Injection
Description: Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4)Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.
Study NCT04785768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate Sustained-release Tablets
Description: Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for day 1; 2）the total equianalgesic of the previous 24 hours/2 for day 2 ; 3）Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；4) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours;
Study NCT05792761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b combined and ETV
Description: Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300.~1. NA monotherapy group : received entecavir (ETV) for 96 weeks.~2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks.~3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks.
Study NCT06148402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib plus camrelizumab and capecitabine
Description: fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w
Study NCT04999605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 low dose
Description: AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor
Study NCT04999605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 medium dose
Description: AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor
Study NCT04999605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 high dose
Description: AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor
Study NCT05585736 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cycloplegics
Description: they are drugs that paralyze the ciliary muscles and cause relaxation of accommodation.
Study NCT05544318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diatary advices
Description: Advice regarding energy, protein and nutrient intake during cancer treatment
Study NCT05974683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
Study NCT05974683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
Study NCT06194812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pain Catastrophizing scale
Description: Participants' fear and avoidance behaviors will be evaluated with the Fear Avoidance Beliefs Questionnaire (KKBS) (Appendix 2).~Participants' fear of movement will be evaluated with the Tampa Kinesiophobia Scale (TKS) (Appendix 3).~Pain Catastrophizing Scale (PAS) (Appendix 4) will be used to evaluate the participants' pain-related thoughts and feelings.~The amount of improvement in symptoms perceived by the participants will be evaluated at the end of the treatment with the Global Perceived Impact Scale (GAES) (Appendix 5). Participants were asked How would you describe your current situation compared to the beginning of treatment? question will be asked.
Study NCT05091619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: Intramuscular injection
Study NCT05091619 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed
Description: Intramuscular injection
Study NCT05091619 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine
Description: Intramuscular injection
Study NCT04930653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: Undergo ECP
Study NCT04930653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Given IV
Study NCT04930653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04930653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05460637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No BS just Fitness
Description: The participants receive lessons on the physical activity guidelines, goal setting, physical activity planning, habit development, identity formation, and how to apply all these tools together. In addition, there are numerous resources provided to other existing web resources, including exercise videos and other informational webpages (e.g., USDA nutritional recommendations).
Study NCT05258799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count > 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
Study NCT05636982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecare-based intervention program
Description: A 3-month telecare-based intervention program
Study NCT04858360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emla 1 hour
Description: At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.
Study NCT04858360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA 3 hours
Description: At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 3 hours.
Study NCT04858360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle cream for 1 hour
Description: At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 1 h.
Study NCT04858360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle cream for 3 hours
Description: At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 3 h.
Study NCT04858360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
Study NCT05056571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: Progressive muscle relaxation exercise is a type of exercise in which tense muscles in your body gradually relax and relax. It is an application that allows you to forcefully stretch every muscle group in your body, hold it tight for 5 seconds, and then relax it. Visualize your tense muscles throughout this exercise and imagine that the feeling of relaxation spreads to all your muscles in the form of a wave and the tension is relieved. Keep breathing throughout the entire exercise.
Study NCT05692219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle medicine
Description: 6 weeks booklet-delivered multicomponent lifestyle medicine intervention
Study NCT05692219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: 6 weeks booklet-delivered self-help cognitive behavioral therapy
Study NCT05822128 — intervention group
Intervention type: OTHER
Intervention: Test of an alternative Epworth Sleepiness Scale ESS-ALT in French
Description: Seniors recruited into the study will test the Epworth Alternate Sleepiness Scale -ALT
Study NCT05035797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary rehabilitation
Description: Cardiopulmonary rehabilitation program which encompasses six evidence-based components according to literature review: 1) positioning; 2) passive range of motion (PROM) training; 3) neuromuscular electronic stimulation (NMES); 4) surface electrical phrenic nerve stimulation (SEPNS); 5) PNF techniques; and 6) airway clearance techniques; Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
Study NCT05035797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Control group will be treated with usual care and ECMO therapy. Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
Study NCT05035797 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Control group will be treated with usual care and ECMO therapy. Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
Study NCT05313646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: batch 1 of Ad5-nCoV
Description: The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101001. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
Study NCT05010668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: Cryoablation treatment starts at day 0.
Study NCT05010668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study NCT05010668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study NCT06490601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide and hydroxyurea
Description: Thalidomide:~Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor- alpha Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Hydroxyurea:~Hydroxyurea or hydroxycarbamide (HU) lies in the category of antimetabolite. Mechanism of fetal hemoglobin induction includes increase in erythropoietin and nitric oxide production, apoptosis induction and potentiating in granulocyte cycling activity.
Study NCT06490601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor -alpha , Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Investigating the impact of thalidomide on transfusion-dependent beta thalassemia patients is essential for discerning its therapeutic efficacy and safety profile.
Study NCT05586412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagus nerve stimulation
Description: Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.
Study NCT05216198 — intervention group
Intervention type: OTHER
Intervention: Check of the different exams performed at the emergencies
Description: Check of the different exams performed at the emergencies
Study NCT05632380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection. If previously collected stem cells are available, no stem cell mobilization or collection is required, and patients will receive conditioning directly.
Study NCT05313646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: batch 2 of Ad5-nCoV
Description: The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101002. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
Study NCT05313646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: batch 3 of Ad5-nCoV
Description: The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202102003. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
Study NCT05632380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR088
Description: C-CAR088 is an BCMA targeted Chimeric Antigen Receptor-T cell product. Patients will receive C-CAR088 single dose infusion 3 days after ASCT. The dose level of C-CAR088 will be determined by the investigator.
Study NCT04352738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)
Description: Magnetic resonance scanning for 150 minutes involving ingestion of 60g of 6,6, 2H2-glucose diluted in 200ml of tap water. Frequent blood samples will be drawn for measurements of plasma glucose, insulin, C-peptide and glucagon
Study NCT06147323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Healthy Diet
Description: Participants aged 18-65 years in general good health will be following the Eatwell booklet advice\*and NICE/NHS guidelines (https://www.nice.org.uk/).
Study NCT06147323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Seaweed Group
Description: Participants aged 18-65 prediabetics will take 2 seaweeds brown extract capsules/day (information detailed in the safety product sheet, total dose of 700 mg before each of the two main meals. All participants will be advised on product storage and use conditions prior to use to ensure product consistency throughout the period of the study.
Study NCT06147323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Diet Group
Description: Participants aged 18-65 prediabetics will take 2 capsules/day (750mg Maltodextrin placebo comparator) before each of the two main meals without any advice on the diet to follow.
Study NCT05749497 — intervention group
Intervention type: OTHER
Intervention: NCRT+TME
Description: The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
Study NCT05119569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenebrutinib
Description: Fenebrutinib will be administered orally.
Study NCT05119569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.